Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26148626 | 0.91 | TMPRSS2 (0.37) | TMPRSS2 | |
| SCHEMBL26206567 | 0.90 | TMPRSS2 (0.36) | TMPRSS2 | |
| SCHEMBL25183531 | 0.90 | TMPRSS2 (0.37) | TMPRSS2 | |
| SCHEMBL26317942 | 0.90 | TMPRSS2 (0.40) | TMPRSS2 | |
| SCHEMBL12243202 | 0.90 | TMPRSS2 (0.39) | TMPRSS2 | |
| SCHEMBL25187142 | 0.90 | TMPRSS2 (0.39) | TMPRSS2 | |
| SCHEMBL24313295 | 0.89 | TMPRSS2 (0.37) | TMPRSS2 | |
| SCHEMBL25381843 | 0.89 | TMPRSS2 (0.37) | TMPRSS2 | |
| SCHEMBL25910105 | 0.88 | TMPRSS2 (0.36) | TMPRSS2 | |
| SCHEMBL25910153 | 0.88 | TMPRSS2 (0.36) | TMPRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297226-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240317790-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2024-09-26 | — | — | US | disclosed |
| EP-4424372-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | Gilead Sciences, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-4204421-B1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814406-B2 | Compounds and methods for treatment of viral infections | GILEAD SCIENCES, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4204421-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814406-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885 |
| US-12297226-B2 | Compounds and methods for treatment of viral infections | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885 |
| US-20230151043-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885 |
| US-20240317790-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, ACE | TMPRSS2 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.